Insulin Regular, Concentrated (U-500)

Introduction Overview

Generic Name

insulin regular, concentrated (U-500)

Brand Name

Humulin RU 500, HumuLIN R (Concentrated), HumuLIN R KwikPen (Concentrated)

Dosage Form

Injection (vial and prefilled pen)

Drug Class

Insulin

Pharmacokinetics

Absorption:
Humulin R U-500 insulin is administered subcutaneously and exhibits a delayed onset and prolonged duration compared to standard human regular U-100 insulin owing to its high concentration and reduced absorption rate. Absorption from the subcutaneous tissue occurs gradually over several hours, with the onset of action typically appearing within 30 minutes to 1 hour post injection. Peak insulin activity occurs between 4 to 12 hours, and due to its concentrated formulation, the slow diffusion from the injection site contributes to an extended insulin action profile lasting up to 24 hours. The concentrated nature results in a smaller injection volume which may reduce discomfort and variability in absorption but requires careful dose measurement.

Distribution:
Once absorbed into systemic circulation, Humulin R U-500 distributes similarly to other human insulins. It binds predominantly to insulin receptors on peripheral tissues such as skeletal muscle, adipocytes, and liver cells to induce glucose uptake. The volume of distribution approximates plasma volume due to limited extravascular distribution. Protein binding is minimal, as insulin acts primarily at cell membrane receptors. The concentrated formulation does not alter systemic distribution profiles compared to standard insulin; however, monitoring for distribution-related effects is important given the higher potency per volume.

Metabolism:
Insulin is primarily metabolized by insulin-degrading enzymes in the liver, kidneys, and peripheral tissues. Hepatic metabolism accounts for approximately 60% of insulin degradation, with renal clearance contributing the remainder. Humulin R U-500 undergoes the same enzymatic degradation pathways as other human insulins. Its concentrated formulation does not impact metabolic enzymatic processing, but patients with hepatic or renal impairment may experience altered insulin clearance necessitating dose adjustments. The metabolism results in inactive metabolites excreted via renal and biliary routes.

Elimination:
Elimination of Humulin R U-500 insulin occurs mainly through metabolic degradation rather than renal excretion of unchanged drug. The half-life is short (about 4-6 minutes for insulin in plasma), but the pharmacodynamic effect duration is prolonged due to sustained absorption from subcutaneous tissue. Concentrated formulation minimizes injection volume and prolongs absorption, thereby extending action rather than affecting elimination pathways. Clearance may be reduced in kidney or liver dysfunction, increasing the risk of hypoglycemia. Monitoring and individualization of dosing are critical in such populations.

Dosage Forms

Available Dosage Forms:
Humulin R U-500 is available as a concentrated insulin formulation containing 500 units of insulin per mL, which is five times the concentration of standard U-100 insulin. It is supplied in two primary dosage forms: a vial and a prefilled injection pen (HumuLIN R KwikPen U-500). The vial formulation requires the use of specialized U-500 insulin syringes for accurate dosing, and the pen device allows for dialed doses specifically calibrated for U-500 insulin.

Dosages for Adults and Adolescents:
The dosage of Humulin R U-500 is individualized based on the patient's insulin requirements, glucose monitoring results, and glycemic control goals. It is primarily indicated for adults and children with significant insulin resistance requiring more than 200 units of insulin per day. Initial dose calculations should consider previous total daily insulin use, and careful titrations are performed to avoid hypoglycemia. Due to the high potency, doses must be measured precisely using appropriate devices without conversion factors when using the pen or syringes designed for U-500 insulin.

Specific Patient Populations:
Special considerations exist for patients with hepatic or renal impairment due to possible altered metabolism and elimination of insulin, requiring dose adjustments and close monitoring. Pregnant or breastfeeding women should manage diabetes carefully with clinicians to balance maternal glycemic control and fetal safety. Pediatric dosing is less common but may be used under specialist supervision in children with severe insulin resistance. Elderly patients may have increased sensitivity to insulin's effects and need cautious dose adjustments.

The unique feature of U-500 insulin is its concentrated formulation, which reduces injection volume and may improve adherence for patients with high daily insulin requirements but also increases the risk of dosing errors if standard insulin devices or doses are incorrectly used.

Mechanism Of Action

Humulin R U-500 insulin is a concentrated formulation of human regular insulin, which mimics endogenous insulin to regulate glucose metabolism. Insulin exerts its primary effects by binding to the insulin receptor, a transmembrane tyrosine kinase receptor, on the surface of target cells such as muscle, fat, and liver tissues. This binding triggers receptor autophosphorylation and initiates a cascade of intracellular signaling pathways.

The activated insulin receptor recruits and phosphorylates insulin receptor substrates (IRS), which further activate phosphatidylinositol 3-kinase (PI3K) and downstream protein kinase B (Akt). This signaling results in the translocation of glucose transporter 4 (GLUT4) to the cell membrane in muscle and adipose tissues, promoting facilitated glucose uptake from the bloodstream into these cells. Concurrently, insulin inhibits hepatic gluconeogenesis and glycogenolysis, reducing endogenous glucose production.

At the biochemical level, insulin regulates carbohydrate, lipid, and protein metabolism by promoting glycogen synthesis, lipogenesis, and protein synthesis while inhibiting lipolysis, proteolysis, and ketogenesis. The concentrated U-500 formulation differs from standard U-100 insulin mainly by a fivefold increase in insulin concentration, which enables delivery of high insulin doses in smaller volumes, beneficial in severely insulin-resistant patients.

Clinically, this extended and efficacious action profile of Humulin R U-500 permits basal and prandial coverage with fewer injections, but requires careful administration to avoid hypoglycemia or dosing errors. Compared to rapid-acting insulin analogs, U-500 insulin has a slower onset but prolonged duration, positioned between intermediate and long-acting insulin profiles, making it suitable for patients with markedly elevated insulin needs. Clinical studies have demonstrated its efficacy in improving glycemic control in patients with severe insulin resistance while reducing injection burden.

Pharmacological Actions

Lowers blood glucose by facilitating cellular uptake of glucose primarily into muscle and adipose tissues.
Suppresses hepatic glucose production through inhibition of gluconeogenesis and glycogenolysis.
Promotes glycogen synthesis in liver and muscle, enhancing glucose storage.
Stimulates lipogenesis and inhibits lipolysis, thereby promoting fat storage and reducing circulating free fatty acids.
Enhances protein synthesis while inhibiting proteolysis, contributing to anabolic effects.
Long-acting insulin effect with onset within 30-60 minutes and duration up to 24 hours due to concentrated U-500 formulation and slower absorption.
Reduces blood glucose peaks post-meal and maintains basal glycemic control in insulin-resistant patients.
Modifies cellular metabolism and gene expression related to glucose homeostasis.
Provides sustained insulin activity, reducing the frequency of injections in patients requiring high doses.
Improves overall glycemic control and reduces HbA1c levels in patients with severe insulin resistance.
Facilitates metabolic control in both type 1 and type 2 diabetes mellitus where high insulin doses are required.

Therapeutic Or Clinical Uses

Management of type 1 and type 2 diabetes mellitus with high insulin requirements exceeding 200 units/day.
Treatment of severe insulin resistance in adult and pediatric diabetic patients.
Glycemic control improvement in patients inadequately controlled on standard insulin regimens.
Reducing injection volume and frequency in patients needing large doses of insulin.
Adjunct to diet, exercise, and other antidiabetic medications in complex diabetes management.
Use in patients who require basal and prandial insulin coverage due to prolonged action.
Therapy in patients where volume overload or injection burden must be minimized.
Potential off-label use in insulin-resistant conditions as determined by clinicians.
Utility in hospitalized patients requiring tight glucose control but with high insulin demands.
Treatment of hyperglycemia to prevent acute and chronic complications of diabetes.
Facilitating improved compliance in patients struggling with multiple daily injections.

Side Or Adverse Effects

Hypoglycemia is the most common and serious side effect, which may manifest as shakiness, confusion, sweating, and in severe cases, seizures or loss of consciousness.
Injection site reactions including redness, swelling, itching, or lipodystrophy (thickening or pitting of skin).
Allergic reactions ranging from mild rash and itching to rare anaphylaxis.
Fluid retention leading to peripheral edema and potential weight gain.
Hypokalemia (low potassium levels) presenting with muscle cramps, cardiac arrhythmias, and weakness.
Rare local allergic reactions such as swelling or redness at the injection site.
Risk of insulin overdose leading to life-threatening hypoglycemia if dosing errors occur.
Swelling or difficulty breathing in cases of severe hypersensitivity.
Potential for lipohypertrophy or lipoatrophy with repeated injections at same site.
Possible allergic rash with generalized itching or systemic involvement.
Injection site infections if aseptic technique is not maintained during administration.
Transient neuropathic pain or hypersensitivity at injection sites.
Weight gain associated with insulin therapy.
Rare occurrence of insulin antibody formation affecting insulin action.

Precautions

Do not use during episodes of hypoglycemia; insulin will further lower blood glucose.
Use cautiously in patients with hepatic or renal impairment due to altered insulin metabolism.
Monitor potassium levels closely, especially if used in conjunction with medications that affect potassium balance.
Avoid switching between insulin products without medical supervision to prevent dosing errors.
Ensure correct dosing using only U-500 specific syringes or pens to prevent overdose.
Educate patients to rotate injection sites to minimize lipodystrophy.
Be aware of increased risk of heart failure when used with thiazolidinediones (pioglitazone, rosiglitazone).
Patients should carry medical identification indicating insulin use for emergency situations.
Avoid alcohol consumption which may exacerbate hypoglycemia.
Exercise caution in elderly patients who may have impaired hypoglycemia awareness.
Regular blood glucose monitoring is essential to adjust doses accurately.
Use caution in pregnant or breastfeeding women; insulin requirements may change.
Never share insulin pens, cartridges, or syringes to reduce infection risk.
Store insulin properly; do not freeze or expose to extreme temperatures.

Warnings

Never share injection pens, cartridges, or syringes with others to prevent cross-infection.
Strictly adhere to dosing instructions; incorrect dosing can cause severe hypoglycemia or hyperglycemia.
U-500 insulin should never be administered intravenously or via insulin pumps.
Do not mix U-500 insulin with other insulin products to avoid unpredictable effects.
Immediate medical attention is required if signs of insulin allergy appear such as swelling, rash, or breathing difficulties.
Carefully assess for signs of fluid retention and congestive heart failure during treatment.
Patients using oral diabetes agents like pioglitazone with U-500 insulin have increased risk of serious heart problems.
Risk of severe hypoglycemia increases if patient meals are delayed or missed after injection.
Proper patient education is critical to prevent medication errors and hypoglycemic events.
Discard any insulin that appears cloudy, discolored, or contains particles.
Monitor patients closely during changes in insulin regimens or concomitant medications.
Inform patients about symptoms of hypo- and hyperglycemia and emergency measures.
Store injection pens without needles attached to prevent contamination.
Pregnant women must manage insulin dosing carefully to avoid fetal complications.
Keep insulin out of reach of children to prevent accidental overdose.

Contraindication

Known hypersensitivity or allergy to insulin or any of the formulation components.
During episodes of hypoglycemia or low blood glucose levels.
In patients with hypokalemia unless potassium levels are corrected.
Do not use in insulin pumps or intravenous administration routes.
Contraindicated in patients who cannot accurately measure or administer U-500 insulin doses due to risk of overdose.
Use cautiously or avoid in patients with severe liver or kidney dysfunction without careful monitoring.
Avoid in patients with active infections or skin lesions at injection sites.
Contraindicated without medical supervision in pregnant women unless benefits outweigh risks.
Do not administer to patients with unstable or unmonitored diabetes due to risk of unpredictable glycemic response.
Avoid co-administration with other insulins unless prescribed by a healthcare professional.
Contraindicated if patient is unwilling or unable to perform regular blood glucose monitoring.
Patients with disorders influencing potassium homeostasis should be closely monitored before use.
Not recommended in patients with hypoglycemia unawareness without specialist management.
Avoid use when proper storage of insulin cannot be ensured.
Contraindicated in individuals with a history of severe insulin allergy or anaphylaxis.

Drug Interactions

Concomitant use with oral antidiabetic agents such as pioglitazone or rosiglitazone can increase risk of heart failure and exacerbate fluid retention.
Beta-blockers may mask symptoms of hypoglycemia and inhibit recovery by impairing glycogenolysis.
Diuretics and corticosteroids may increase blood glucose, requiring insulin dose adjustment.
Alcohol consumption potentiates hypoglycemic effects and can impair glucose recovery.
ACE inhibitors may enhance the blood glucose lowering effects of insulin.
Several antibiotics like fluoroquinolones can affect blood glucose levels unpredictably in diabetic patients.
Salicylates and some oral anticoagulants can potentiate hypoglycemia when combined with insulin.
Thyroid hormone replacement may alter insulin requirements by changing metabolic rate.
Sympathomimetic agents such as epinephrine may antagonize insulin action, increasing glucose levels.
Somatostatin analogs may reduce insulin secretion and affect glycemic control in combination therapy.
Certain antipsychotics and antidepressants can cause hyperglycemia, altering insulin needs.
Interactions with SGLT2 inhibitors can increase risk of ketoacidosis, requiring monitoring.
Herbal products like ginseng or fenugreek may have additive hypoglycemic effects.
Drugs that affect potassium levels (e.g., potassium-wasting diuretics) can worsen hypokalemia risk during insulin therapy.
Flu vaccines and illness can alter insulin requirements due to stress response.

Preparations Of The Drug

Humulin R U-500 vial: 20 mL vial containing 500 units/mL of insulin regular, concentrated.
Humulin R U-500 KwikPen: Prefilled pen with 3 mL containing 1500 units of insulin U-500 for subcutaneous injection.
U-500 insulin syringes specifically designed for accurate dosing of U-500 insulin from vial preparations.
Injection pens with dosing dials calibrated specifically for U-500 doses to avoid conversion errors.
Storage instructions include refrigeration of unopened vials and pens until use; opened vials stable refrigerated up to 40 days and pens at room temperature up to 28 days.
Prefilled pens should be stored without needle attached to prevent contamination and air ingress.
No admixture or dilution with other insulins or solutions is recommended or safe for U-500 insulin use.
All preparations require patient or caregiver instruction regarding specific devices and dosing procedures.
Sharps disposal containers are recommended and required for safe disposal of needles and syringes after use.
Preparation instructions emphasize ensuring clarity of solution and avoidance of product with discoloration or particulate matter.
Vials are intended for multiple doses, handled under sterile conditions to reduce contamination risk.
Commercial packaging typically includes detailed patient education leaflets and administration guides.
Devices and packaging are labeled clearly to emphasize the concentrated nature to prevent dosing errors.
Supplementary materials and instructions for use are provided by manufacturers for healthcare professionals.
Patient programs may support education and safe handling of U-500 insulin products.